Medical research charity lands £1bn from sale of royalties in cancer drug
LifeArc has sold its stake in pembrolizumab and will use the money to fund further research
A medical research charity has earned £1bn from the sale of its royalties in a cancer drug, becoming one of the UK’s richest charities as a result.
LifeArc owned a stake in the drug pembrolizumab, also known by the brand name Keytruda, which it sold to CPPIB Credit Europe S.a.r.l. for $1.3bn, equivalent to about £1bn,,
Ann: Appendix 4C and Quarterly Update, page-54
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NUZ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
0.010(5.41%) |
Mkt cap ! $95.88M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 19.5¢ | 19.0¢ | $66.44K | 346.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 36359 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 12500 | 2 |
View Market Depth
| Last trade - 13.26pm 13/11/2024 (20 minute delay) ? |
| NUZ (ASX) Chart |